Evotec Appoints Dr. Werner Lanthaler as Chief Executive Officer

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ:
EVTC) announced today the appointment of Dr. Werner Lanthaler as
Chief Executive Officer of the Company, effective immediately. In his
previous position, Dr. Lanthaler served as Chief Financial Officer of
Intercell AG in Vienna, Austria, a global biopharmaceutical leader
dedicated to the development of vaccines. In this role, he was also
responsible for Business Development and Marketing & Sales.

Dr. Lanthaler had eight very successful years at Intercell AG where
he served since 2001. During his tenure, Intercell developed from a
venture-backed biotechnology company into a global vaccine player.
Dr. Lanthaler played a pivotal role in many of the company's major
corporate milestones including the most recent product approval of
Intercell's Japanese Encephalitis Vaccine, the company's acquisitions
and strategic pharma partnerships, as well as the company's Initial
Public Offering on the Vienna Stock Exchange in 2005.

Previously, Dr. Lanthaler served as Director of the Federation of
Austrian Industry and as Senior Management Consultant at the
consulting firm McKinsey & Company. He holds a doctorate in economics
from Vienna University, earned his Master's degrees from Harvard
University, and holds a degree in Psychology.

Dr. Flemming Ørnskov, Chairman of the Supervisory Board of Evotec,
stated: "Dr. Lanthaler is an ideal candidate to be CEO of Evotec at
this juncture. His experience in building a highly successful
company, his impressive track record in business and corporate
development, and his strong sense for the creation of shareholder
value are a perfect match with Evotec's strategy to transform itself
into a streamlined biopharmaceutical company. In summary, he brings
all the skills and experience needed in order to adapt and shape
Evotec's strategy and move the Company to the next level of success."

"I look forward to joining this exciting company in a challenging
market environment. It possesses an abundance of opportunities based
on good fundamental science, an excellent reputation for drug
discovery and development, and strong financial resources. It is my
goal to advance Evotec's vision and generate significant shareholder
value in the years to come", stated Dr. Werner Lanthaler, the Chief
Executive Officer of Evotec.

If you have any questions, please contact:

Dr. Flemming Ørnskov
Chairman of the Supervisory Board
+49 160 7158213
flemming.ornskov@bausch.com

Dr. Werner Lanthaler
Chief Executive Officer
+ 49 40 56081242
werner.lanthaler@evotec.com

Anne Hennecke
SVP, Investor Relations & Corporate Communications
+49 40 56081286
anne.hennecke@evotec.com

Forward-Looking Statements
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to,
statements about our expectations and assumptions concerning
regulatory, clinical and business strategies, the progress of our
clinical development programs and timing of the results of our
clinical trials, strategic collaborations and management's plans,
objectives and strategies. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond our control, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and
uncertainties include, among other things: risks that product
candidates may fail in the clinic or may not be successfully marketed
or manufactured; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in
clinical trials; our inability to further identify, develop and
achieve commercial success for new products and technologies;
competing products may be more successful; our inability to interest
potential partners in our tecnologies and products; our inability to
achieve commercial success for our products and technologies; our
inability to protect our intellectual property and the cost of
enforcing or defending our intellectual property rights; our failure
to comply with regulations relating to our products and product
candidates, including FDA requirements; the risk that the FDA may
interpret the results of our studies differently than we have; the
risk that clinical trials may not result in marketable products; the
risk that we may be unable to successfully secure regulatory approval
of and market our drug candidates; and risks of new, changing and
competitive technologies and regulations in the U.S. and
internationally.

The list of risks above is not exhaustive. Our Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other
documents filed with, or furnished to the Securities and Exchange
Commission, contain additional factors that could impact our
businesses and financial performance. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on
which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480; ISIN:
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All
Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt
in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.